How to cite
Pageaud Y., Plass C., Assenov Y. (2018)
Enrichment Analysis with EpiAnnotator.
Bioinformatics.
Impressum
EpiAnnotator is developed by the
Computational Epigenomics
group in the
Division of Epigenomics and Cancer Risk Factors
at the
German Cancer Research Center (DKFZ)
- Heidelberg, Germany.
(c) 2017 EpiAnnotator, German Cancer Research Center (DKFZ).
This web site is hosted by:
- Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ).
Address:
- Deutsches Krebsforschungszentrum
- Im Neuenheimer Feld 280
- D-69120 Heidelberg
- Germany
Phone:
+49 6221 420
Fax:
+49 6221 422995
Internet:
www.dkfz.de
E-mail:
kontakt@dkfz.de
Legal Form:
- Deutsches Krebsforschungszentrum
- Stiftung des öffentlichen Rechts (Foundation under Public Law)
Value added tax identification number:
DE 143293537
Persons authorised to represent:
- Division Epigenomics and Cancer Risk Factors Head: Prof. Dr. Christoph Plass
- Group Leader: Dr. Yassen Assenov
- Bioinformatics Engineer: M.Sc. Yoann Pageaud
Persons responsible for the internet presence:
- Group Leader: Dr. Yassen Assenov
- Bioinformatics Engineer: M.Sc. Yoann Pageaud
Disclaimer:
This website offers the opportunity to perform
enrichment analysis on genomic regions and methylation data.
Our goal is to provide (epi)-genomic annotations coming from
various repositories (GENCODE, UCSC, BLUEPRINT, ROADMAP Epigenomics)
and to update them every 2 months. If errors are brought to our
attention, we will try to correct them.
Data Protection Provisions:
The EpiAnnotator team is committed to protecting the privacy of all
persons using its website. The data is used exclusively for the
purposes indicated and not disclosed to third parties. Without your
knowledge, your web browser or client software may transfer
information about your computer (for example IP address) to our
server. Such information is never brought directly in touch with you,
and is not used by our service.
This applies also to:
- Twitter Account: https://twitter.com/EpiAnnotator
- Biostars Topic: https://www.biostars.org/p/293496/
Twitter Account - @EpiAnnotator
This is a Twitter account created for EpiAnnotator announcement and
we encourage you to leave comments, photographs, videos or links
related to the theme of this account that would enrich the community.
In order to foster a courteous climate and respectful exchanges,
rules of good conduct have been defined. The moderator may be
required to delete a contribution that:
-
Would be contrary to public order, morality or laws and
regulations (eg violent, erotic, pornographic, racist
content, ...)
- Would not respect the code of intellectual property
-
Would be offensive, rude, vulgar, or likely to offend the
sensitivity of minors
- Would be of a commercial or political nature
The user, by tweeting to @EpiAnnotator, retweeting or liking any
content from @EpiAnnotator, accepts fully and without any reserve the
present charter of use, and commits himself, during each of its
visits on the profile, to the respect.
Administrators reserve the right to delete any comment or tweet
deemed inappropriate and also reserve the right to modify the user's
charter without notice.
Biostars Topic
This is a Biostars topic created for EpiAnnotator's users. We
encourage you to report bugs, errors and comments related to the
theme of this post that would enrich the community.
In order to foster a courteous climate and respectful exchanges,
rules of good conduct have been defined. The moderator may be
required to delete a contribution that:
-
Would be contrary to public order, morality or laws and
regulations (eg violent, erotic, pornographic, racist
content, ...)
- Would not respect the code of intellectual property
-
Would be offensive, rude, vulgar, or likely to offend the
sensitivity of minors
- Would be of a commercial or political nature
The user, by commenting, accepts fully and without any reserve the
present charter of use, and commits himself, during each of its
visits on the topic, to the respect.
Administrators reserve the right to delete any comment deemed
inappropriate and also reserve the right to modify the user's charter
without notice.